Department of Hematology, Oncology and Cardiovascular Medicine, Kyushu University Hospital, Maidashi 3-1-1, Higashi-ku, Fukuoka 812-8582, Japan.
Department of Hematology, Oncology and Cardiovascular Medicine, Kyushu University Hospital, Maidashi 3-1-1, Higashi-ku, Fukuoka 812-8582, Japan.
Heart Fail Clin. 2020 Apr;16(2):231-241. doi: 10.1016/j.hfc.2019.11.002. Epub 2020 Feb 11.
Several cancer treatments cause cardiotoxicity that can lead to heart failure, coronary artery disease, arrhythmia, and pericardial disease. In this review, representative cases of heart failure following cardiotoxicity caused by trastuzumab, anthracycline, and hematopoietic stem cell transplantation are described with case notes. Additionally, other important points regarding cardiotoxicity related to heart failure are reported. During and after potentially cardiotoxic therapy, periodic cardiac examinations are recommended to detect any cardiovascular disorders; these are ameliorated if appropriately diagnosed at an earlier stage. It is important for cardiologists and oncologists to understand the pathophysiology of representative cardiovascular disease cases following cancer treatment.
几种癌症治疗方法可引起心脏毒性,导致心力衰竭、冠状动脉疾病、心律失常和心包疾病。在这篇综述中,我们通过病例报告描述了曲妥珠单抗、蒽环类药物和造血干细胞移植引起心脏毒性后心力衰竭的代表性病例。此外,还报告了与心力衰竭相关的其他重要心脏毒性问题。在潜在的心脏毒性治疗期间和之后,建议定期进行心脏检查,以发现任何心血管疾病;如果在早期阶段得到适当诊断,则可以改善这些疾病。心脏病专家和肿瘤学家了解癌症治疗后代表性心血管疾病病例的病理生理学非常重要。